Positive clinical trial results for GSK and Ochre Bio liver disease treatment by end of 2024? | Binary | | | 6 months ago | |
Ochre Bio secures third pharma collaboration by end of 2024? | Binary | | | 6 months ago | |
GSK and Ochre Bio extend $37.5M data licence agreement by June 2025? | Binary | | | 6 months ago | |
Timeline for first new liver disease therapy post GSK-Ochre Bio collaboration? | Categorical | | | 6 months ago | |
Ochre Bio's next major milestone announcement? | Categorical | | | 6 months ago | |
Market cap change for Ochre Bio post data licence agreement by end of 2024? | Categorical | | | 6 months ago | |
Ochre Bio hits first partnership milestone by end of 2024? | Binary | | | 8 months ago | |
Ochre Bio's treatment in clinical trials by 2025? | Binary | | | 8 months ago | |
Clinical trial phase progression of Ochre Bio's treatment by 2026 | Categorical | | | 8 months ago | |
Total Boehringer Ingelheim payments to Ochre Bio by end of 2025 | Categorical | | | 8 months ago | |
Scope expansion of Ochre Bio's treatments by end of 2025 | Categorical | | | 8 months ago | |
Søren Tullin remains at his position through 2024? | Binary | | | 8 months ago | |
